/
Other
Combination Therapy
47
Pipeline Programs↗
33
Active Trials↗
52
Companies Involved↗
Combination Therapy is a moderately active landscape with 47 programs across 52 companies. The most active players are Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shenyang Sunshine Pharmaceutical Co., LTD.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
SPhase 2JPhase 1SPhase 2SPhase 2
Phase 2SPreclinical
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2 programs
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2 programs
Shenyang Sunshine Pharmaceutical Co., LTD.
1 program
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
1 program
Pfizer
1 program
Shanghai EpimAb Biotherapeutics Co., Ltd.
1 program
Pipeline
Programs by Phase
Preclinical11
Phase 110
Phase 225
Phase 31
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
36 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 100% of 47 pipeline programs.
Analysis
Trial Status
213
clinical trials
Completed116 · 54%
Unknown status42 · 20%
Recruiting16 · 8%
Terminated15 · 7%
Not yet recruiting14 · 7%
Withdrawn7 · 3%
Other3 · 1%
Clinical Trials
Trial Activity
213 trials
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07330050·31 enrolled
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Recruiting·—·N/A·NCT06457477·50 enrolled
Comparison of Sequential to Initial Combination Therapy in PAH
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06968962·376 enrolled
Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm
Recruiting·—·N/A·NCT04302116·250 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)